Shanghai Bio-heart Biological Technology Co., Ltd.

SEHK:2185 Stock Report

Market Cap: HK$433.3m

Shanghai Bio-heart Biological Technology Past Earnings Performance

Past criteria checks 0/6

Shanghai Bio-heart Biological Technology has been growing earnings at an average annual rate of 16.1%, while the Medical Equipment industry saw earnings growing at 14.7% annually.

Key information

16.1%

Earnings growth rate

43.3%

EPS growth rate

Medical Equipment Industry Growth13.7%
Revenue growth raten/a
Return on equity-16.4%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

Nov 15
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Jul 24
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Feb 22
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Nov 03
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

May 12
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn

Sep 19
We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn

Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Jun 03
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown

How Shanghai Bio-heart Biological Technology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2185 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-1162965
31 Mar 240-1464188
31 Dec 230-17653112
30 Sep 230-18262133
30 Jun 230-18971155
31 Mar 230-19783156
31 Dec 220-20494158
30 Sep 220-234120161
30 Jun 220-263145165
31 Mar 220-312170190
31 Dec 210-361195214
30 Sep 210-437190284
30 Jun 210-512184354
31 Mar 210-419133300
31 Dec 200-32682246

Quality Earnings: 2185 is currently unprofitable.

Growing Profit Margin: 2185 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2185 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.1% per year.

Accelerating Growth: Unable to compare 2185's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2185 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.3%).


Return on Equity

High ROE: 2185 has a negative Return on Equity (-16.37%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies